Novo Nordisk
NVO
1,482 hedge funds and large institutions have $21.3B invested in Novo Nordisk in 2025 Q2 according to their latest regulatory filings, with 135 funds opening new positions, 582 increasing their positions, 570 reducing their positions, and 162 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 582 | Existing positions reduced: 570
0% more funds holding in top 10
Funds holding in top 10: 25 → 25 (0)
0.37% less ownership
Funds ownership: 7.31% → 6.94% (-0.37%)
3% less funds holding
Funds holding: 1,531 → 1,482 (-49)
6% less capital invested
Capital invested by funds: $22.5B → $21.3B (-$1.24B)
17% less first-time investments, than exits
New positions opened: 135 | Existing positions closed: 162
30% less call options, than puts
Call options by funds: $1.14B | Put options by funds: $1.63B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$293M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$144M |
| 3 |
Morgan Stanley
New York
|
+$134M |
| 4 |
ClearBridge Investments
New York
|
+$108M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$84.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
-$332M |
| 2 |
Two Sigma Advisers
New York
|
-$236M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$220M |
| 4 |
D.E. Shaw & Co
New York
|
-$176M |
| 5 |
JP Morgan Chase
New York
|
-$148M |
NVO Hedge Fund Activity: Q2 2025 in Review
1,482 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2025, worth a combined $21.3B — down 5.5% from $22.5B a quarter earlier.
Sellers outnumbered buyers: 162 funds closed out of NVO and 135 opened new positions — a net loss of 27 holders — while 570 trimmed existing stakes and 582 added.
The largest buyer was Fidelity Investments, adding an estimated $293M. The largest seller was Amundi, exiting entirely with an estimated $332M sold.
- 1,482 institutional investors held Novo Nordisk (NVO) as of Q2 2025, down from 1,531 in Q1 2025.
- Funds reported $21.3B of Novo Nordisk stock for Q2 2025, down 5.5% quarter-over-quarter.
- 135 funds opened new Novo Nordisk positions in Q2 2025 and 162 closed out, a net change of -27 holders.
- The largest Novo Nordisk buyer in Q2 2025 was Fidelity Investments, an estimated $293M added.
- The largest Novo Nordisk seller in Q2 2025 was Amundi, an estimated $332M sold.
Based on aggregated 13F filings for Q2 2025.